Medicare GLP-1 Coverage for Weight Loss: Cost, Criteria & Covered Drugs
A major Medicare change may help more patients access GLP-1 medications for weight loss — but not everyone will qualify, and the rules depend on your BMI, medical history, diagnosis, and prescription coverage.
Founder & Medical Director, JourneyLite Physicians and JourneyLite Surgery Center
For years, one of the most frustrating issues in obesity medicine has been that highly effective medications were often financially out of reach. Patients would ask about Wegovy®, Zepbound®, or other GLP-1 medications, only to find out that their plan did not cover treatment for weight loss, or that the out-of-pocket cost was hundreds or even more than a thousand dollars per month.
That is starting to change for some Medicare patients. Beginning July 1, 2026, Medicare began the Medicare GLP-1 Bridge, a temporary CMS program designed to provide eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight management.
What GLP-1 medications are covered under the Medicare GLP-1 Bridge?
According to Medicare and CMS guidance, the Medicare GLP-1 Bridge currently includes the following drugs when prescribed for weight management in eligible beneficiaries:
Foundayo®
Tablet
Covered formulations of Foundayo® are included in the Medicare GLP-1 Bridge for eligible patients.
Wegovy®
InjectionTablet
Wegovy® injection and tablet formulations are listed by Medicare as covered Bridge medications for eligible patients.
Zepbound®
KwikPen® only
Zepbound® KwikPen® is included. Medicare notes that single-dose Zepbound® vials and single-dose pens are not included in the Bridge program.
Medication lists and National Drug Codes may be updated by CMS over time. Patients should confirm current eligibility and availability through Medicare, their provider, and their pharmacy.
Who qualifies for Medicare GLP-1 coverage for weight loss?
The Medicare GLP-1 Bridge is not simply “GLP-1 coverage for everyone.” A provider must submit a prescription and, when requested, a prior authorization showing that the patient meets program requirements.
Basic requirements
- You must have Medicare drug coverage, usually through a Part D plan or Medicare Advantage plan with drug coverage.
- You must be at least 18 years old.
- The medication must be prescribed to reduce excess body weight and maintain weight reduction.
- The medication must be used with ongoing lifestyle modification, including structured nutrition and physical activity.
- You must meet BMI and medical-condition criteria at the time GLP-1 therapy is initiated.
BMI 35 or higher
Potential Medicare GLP-1 Bridge Criteria
May qualify based on BMI alone if the patient meets the other Medicare GLP-1 Bridge requirements.
Qualifying Conditions
No additional listed comorbidity is required under this BMI category, but medical appropriateness still must be determined by the prescribing clinician.
BMI 30–34.99
Potential Medicare GLP-1 Bridge Criteria
May qualify if at least one qualifying obesity-related condition is present.
Examples of Qualifying Conditions
- Diastolic heart failure / heart failure with preserved ejection fraction, also called HFpEF
- Uncontrolled hypertension
- Chronic kidney disease stage 3a or higher
- Prediabetes
- Prior heart attack or prior stroke
- Symptomatic peripheral artery disease
BMI 27–29.99
Potential Medicare GLP-1 Bridge Criteria
May qualify if at least one higher-risk cardiovascular or metabolic condition is present.
Examples of Qualifying Conditions
- Prediabetes
- Prior heart attack
- Prior stroke
- Symptomatic peripheral artery disease
How much will this cost?
The answer has two parts: the medication cost and the office visit / medical supervision cost.
Medication through Medicare GLP-1 Bridge
Eligible patients pay a $50 copayment at the pharmacy for a one-month supply. Medicare states that this copay does not count toward the Part D deductible or out-of-pocket maximum.
JourneyLite initial medication visit
JourneyLite’s current self-pay medical weight loss pricing lists the initial medication visit at $199. This includes evaluation by our medical weight loss team.
JourneyLite follow-up visits
Follow-up medical weight loss visits are currently listed at $129. Frequency depends on the medication, dose-escalation schedule, side effects, and clinical progress.
If you have Medicare or Medicare Advantage coverage, your office visit cost may depend on your specific plan, deductible, copay, coinsurance, and whether the visit is processed through covered benefits. Medication copays under the Medicare GLP-1 Bridge are separate from office visit costs. JourneyLite will help patients understand expected costs before moving forward.
What about Ozempic®, Mounjaro®, or other diabetes GLP-1 medications?
This is an important distinction. Some GLP-1 medications are approved for type 2 diabetes, while others are approved for chronic weight management, cardiovascular risk reduction, obstructive sleep apnea, or other specific indications.
If a GLP-1 is prescribed for a diagnosis that is already coverable under Medicare Part D — such as type 2 diabetes, certain sleep apnea indications, or other approved medical indications — the medication may be handled through the patient’s regular Part D plan rather than through the Medicare GLP-1 Bridge. In those situations, the patient’s copay is plan-specific and may not be the $50 Bridge copay.
For example, the FDA approved Wegovy® to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and approved Zepbound® for moderate-to-severe obstructive sleep apnea in adults with obesity. Coverage for these uses may run through a Part D plan rather than the Bridge program.
Using GLP-1 medications de novo: starting medication without prior surgery
“De novo” simply means starting GLP-1 therapy as a primary treatment, without having had bariatric surgery first. For some Medicare patients, this may be a very reasonable first step, especially if:
- You qualify under the Medicare GLP-1 Bridge criteria.
- You want a non-surgical starting point.
- You have obesity-related health risks and need help reducing appetite, cravings, and total calorie intake.
- You are willing to commit to structured nutrition, protein goals, activity, and follow-up.
- You understand that GLP-1 medications usually work best as ongoing treatment rather than a short-term “quick fix.”
At JourneyLite, we view GLP-1 medications as one tool in a broader obesity-treatment plan. We also offer surgical, non-surgical, and medication-based options, so the goal is not to push every patient toward the same treatment. The goal is to match the patient to the right tool.
Using GLP-1 medications after bariatric surgery
GLP-1 medications can also be very useful after bariatric surgery. This does not mean that surgery “failed.” Obesity is a chronic, relapsing disease, and even patients who do very well after sleeve gastrectomy, gastric bypass, SADI/SIPS, or Lap Band surgery may later experience:
- A weight-loss plateau
- Gradual weight regain several years after surgery
- Return of appetite or cravings
- Metabolic changes with aging, menopause, medication changes, or decreased activity
- Need for additional help after a revision or complex bariatric history
In post-op patients, GLP-1 therapy can be used to augment the surgical tool. The surgery changes anatomy and physiology; the medication can add appetite control and metabolic support. This combination can be especially helpful when paired with dietitian follow-up, protein targets, lab monitoring, and evaluation for any anatomic issues such as reflux, dilation, or recurrence of maladaptive eating patterns.
Learn more about JourneyLite’s approach to combination therapy for weight regain after bariatric surgery.
How JourneyLite helps patients navigate Medicare GLP-1 coverage
The Medicare GLP-1 Bridge is welcome news, but it also adds a new layer of rules. Patients may not know whether they qualify through the Bridge, through their regular Part D plan, or not at all. Our team can help sort through:
Clinical fit
We review BMI, weight history, medical conditions, prior bariatric surgery, medication history, contraindications, and side-effect risks.
Coverage pathway
We help determine whether the medication may fall under the Medicare GLP-1 Bridge, regular Part D coverage, or a self-pay pathway.
Long-term plan
We pair medication with nutrition coaching, dose management, follow-up, and discussion of surgery or other options when appropriate.
Helpful internal resources
Medicare GLP-1 Coverage FAQ
Does Medicare now cover GLP-1 medications for weight loss?
For some patients, yes. Beginning July 1, 2026, eligible Medicare Part D beneficiaries may access certain GLP-1 medications for weight management through the temporary Medicare GLP-1 Bridge. Patients must meet program criteria and obtain prior authorization when requested.
Which GLP-1 medications are included?
Medicare currently lists Foundayo® tablets, Wegovy® injection or tablets, and Zepbound® KwikPen® as covered Bridge medications for eligible patients. The program does not include Zepbound® single-dose vials or single-dose pens.
How much will the medication cost?
For eligible patients using the Medicare GLP-1 Bridge, the medication copay is $50 for a one-month supply. This copay is separate from office visit costs and does not count toward the patient’s Part D deductible or out-of-pocket maximum.
How much are JourneyLite office visits?
JourneyLite’s current self-pay medication-program pricing lists the initial visit at $199 and follow-up visits at $129. If a patient has Medicare, Medicare Advantage, or other coverage, the actual office visit cost may depend on the plan, deductible, coinsurance, copay, and whether the visit is processed through covered benefits.
Do I qualify if my BMI is under 35?
Possibly. Medicare lists eligibility pathways for patients with BMI 30–34.99 plus certain obesity-related conditions, and for patients with BMI 27–29.99 plus certain higher-risk conditions such as prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
Can I qualify if I already had gastric sleeve or gastric bypass?
Prior bariatric surgery does not automatically mean a patient should or should not use GLP-1 medication. Eligibility depends on current BMI, diagnosis, medical necessity, safety, coverage rules, and prior authorization requirements. Many post-bariatric patients use GLP-1 medications to help with plateaus, weight regain, appetite, or maintenance.
Is Ozempic® covered through the Medicare GLP-1 Bridge?
Ozempic® is generally associated with type 2 diabetes treatment and is not one of the medications listed in the Medicare GLP-1 Bridge for weight management. Diabetes-related GLP-1 prescriptions may be handled through a patient’s regular Part D plan instead, with plan-specific coverage and copays.
Can I use a GLP-1 instead of bariatric surgery?
Some patients can use GLP-1 medication as their primary treatment. Others may get better long-term results from surgery, or from surgery plus medication. The right choice depends on BMI, medical conditions, amount of weight to lose, prior treatment history, side effects, cost, and long-term goals.
External resources
About the Author
Trace Curry, MD, FASMBS is the founder and Medical Director of JourneyLite Physicians and JourneyLite Surgery Center in Cincinnati, Ohio. Dr. Curry has focused his career on bariatric surgery and comprehensive obesity treatment, including gastric sleeve, gastric bypass, SADI/SIPS, revision surgery, gastric balloon therapy, and medical weight management.
At JourneyLite, Dr. Curry and the team help patients compare surgical and non-surgical weight loss options, including GLP-1 medications, with a focus on safety, long-term results, transparent pricing, and individualized care.
Whether you are considering GLP-1 medications for the first time, trying to get back on track after bariatric surgery, or comparing medication versus gastric sleeve, JourneyLite can help you build a plan around your goals, medical history, insurance, and budget.
